SRD5A2 and benign prostatic hyperplasia: To investigate whether AOS treatment can suppress AR-associated pathways, we examined the expression of 5α-reductase type 2 (SRD5A2), AR, and PSA genes in BPH-1 cells in the absence or presence of TP 10 nM.